PANews reported on January 7th that GTreasury has acquired Solvexia, a no-code financial automation platform, aiming to fully integrate reconciliation and regulatoryPANews reported on January 7th that GTreasury has acquired Solvexia, a no-code financial automation platform, aiming to fully integrate reconciliation and regulatory

Ripple's GTreasury acquired Solvexia, advancing the integration of financial automation and compliance.

2026/01/07 11:40

PANews reported on January 7th that GTreasury has acquired Solvexia, a no-code financial automation platform, aiming to fully integrate reconciliation and regulatory reporting into its treasury and compliance platform. This acquisition strengthens GTreasury's "frictionless, borderless" strategy. Combined with Solvexia's data processing and automated reporting capabilities, processes that previously took days can be reduced to minutes, and error rates can be reduced by 98%. The merged platform will support fully automated reconciliation, audit trails, and multi-jurisdictional compliance reporting for both fiat and digital asset transactions, helping companies reduce financial risks and improve transparency and governance efficiency. GTreasury has been continuously expanding its global financial infrastructure capabilities since its acquisition by Ripple in 2025 .

Market Opportunity
Multichain Logo
Multichain Price(MULTI)
$0.03439
$0.03439$0.03439
-1.23%
USD
Multichain (MULTI) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.